(Q37808218)

23 August 2017

title

Immunotherapy of MHC class I-deficient tumors (English)

1 reference

23 August 2017

Immunotherapy of MHC Class I-Deficient Tumors (English)

1 reference

23 August 2024

1 reference

Milan Reiniš

1

1 reference

23 August 2017

language of work or name

English

0 references

publication date

1 October 2010

1 reference

full work available at URL

23 August 2017

http://www.futuremedicine.com/doi/abs/10.2217/fon.10.128

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21062157

https://www.tandfonline.com/doi/pdf/10.2217/fon.10.128

23 August 2024

1 reference

23 August 2024

1 reference

23 August 2017

volume

6

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

1577-1589

1 reference

Immune therapy for cancer

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Implications for immunosurveillance of altered HLA class I phenotypes in human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Viral strategies of immune evasion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Epigenetic mechanisms regulate MHC and antigen processing molecules in human embryonic and induced pluripotent stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

HLA class I antigen expression in malignant cells: why does it not always correlate with CTL-mediated lysis?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

A defect in the presentation of intracellular viral antigens is restored by interferon-gamma in cell lines with impaired major histocompatibility complex class I assembly.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Comparison of cell lines deficient in antigen presentation reveals a functional role for TAP-1 alone in antigen processing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

MHC class I-deficient metastatic tumor variants immunoselected by T lymphocytes originate from the coordinated downregulation of APM components.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Rexpression of HLA class I antigens and restoration of antigen-specific CTL response in melanoma cells following 5-aza-2'-deoxycytidine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

DNA hypermethylation is a mechanism for loss of expression of the HLA class I genes in human esophageal squamous cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Epigenetic control of the immune escape mechanisms in malignant carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Epigenetic enhancement of antigen processing and presentation promotes immune recognition of tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Histone deacetylase inhibitors induce TAP, LMP, Tapasin genes and MHC class I antigen presentation by melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Histone deacetylase regulation of immune gene expression in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Epigenetic regulation of immune escape genes in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

The innate immune response to tumors and its role in the induction of T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

NK cells infiltrating a MHC class I-deficient lung adenocarcinoma display impaired cytotoxic activity toward autologous tumor cells associated with altered NK cell-triggering receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Human natural killer cells: Molecular mechanisms controlling NK cell activation and tumor cell lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Down-regulation of HLA Class I and NKG2D ligands through a concerted action of MAPK and DNA methyltransferases in colorectal cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Interleukin-2 and dendritic cells as adjuvants for surgical therapy of tumours associated with human papillomavirus type 16.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Inhibitory effects of unmethylated CpG oligodeoxynucleotides on MHC class I-deficient and -proficient HPV16-associated tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Induction of protective immunity to RM-1 prostate cancer cells with ALVAC-IL-2/IL-12/TNF-alpha combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Antitumor effects of the combination therapy with TNF-alpha gene-modified tumor cells and interleukin 12 in a melanoma model in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

CD8+ T cells, NK cells and IFN-gamma are important for control of tumor with downregulated MHC class I expression by DNA vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Naked RNA vaccine controls tumors with down-regulated MHC class I expression through NK cells and perforin-dependent pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Antigen presented by tumors in vivo determines the nature of CD8+ T-cell cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

NKG2D ligands in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

In vivo tumor cell rejection induced by NK cell inhibitory receptor blockade: maintained tolerance to normal cells even in the presence of IL-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Glycopeptide dendrimers, part III: a review. Use of glycopeptide dendrimers in immunotherapy and diagnosis of cancer and viral diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Induction of protective immunity against MHC class I-deficient, HPV16-associated tumours with peptide and dendritic cell-based vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Frequency of down-regulation of individual HLA-A and -B alleles in cervical carcinomas in relation to TAP-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Targeting tumour cells with defects in the MHC Class I antigen processing pathway with CD8+ T cells specific for hydrophobic TAP- and Tapasin-independent peptides: the requirement for directed access into the ER.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

The nonpolymorphic MHC Qa-1b mediates CD8+ T cell surveillance of antigen-processing defects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

IFN-gamma-mediated upmodulation of MHC class I expression activates tumor-specific immune response in a mouse model of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Combining the antigen processing components TAP and Tapasin elicits enhanced tumor-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Metastatic MHC class I-negative mouse cells derived by transformation with human papillomavirus type 16

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Enhancement of immunogenicity of HPV16 E7 oncogene by fusion with E. coli beta-glucuronidase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FFON.10.128

The prognostic role of classical and nonclassical MHC class I expression in endometrial cancer

21 January 2018

9

1 reference

Identification of mechanisms underlying transporter associated with antigen processing deficiency in metastatic murine carcinomas

23 August 2024

24

1 reference

Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines

23 August 2024

25

1 reference

Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin

23 August 2024

27

1 reference

HLA class I expression in bladder carcinomas

23 August 2024

29

1 reference

Retinoids act as multistep modulators of the major histocompatibility class I presentation pathway and sensitize neuroblastomas to cytotoxic lymphocytes.

23 August 2024

30

1 reference

Induction of MHC class I molecule cell surface expression and epigenetic activation of antigen-processing machinery components in a murine model for human papilloma virus 16-associated tumours

23 August 2024

35

1 reference

Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction

23 August 2024

42

1 reference

The role of NK1.1+ cells in the protection against MHC class I+ HPV16-associated tumours.

23 August 2024

43

1 reference

Survival of ovarian cancer patients overexpressing the tumour antigen p53 is diminished in case of MHC class I down-regulation

23 August 2024

45

1 reference

Total loss of MHC class I is an independent indicator of good prognosis in breast cancer

23 August 2024

46

1 reference

Natural killer cells infiltrating colorectal cancer and MHC class I expression

23 August 2024

47

1 reference

MHC class I status of tumours and design of immunotherapeutic strategies

23 August 2024

56

1 reference

Animal models for development of therapeutic HPV16 vaccines (review).

23 August 2024

61

1 reference

Therapy for minimal residual tumor disease: beta-galactosylceramide inhibits the growth of recurrent HPV16-associated neoplasms after surgery and chemotherapy

23 August 2024

63

1 reference

Interleukin 12 gene therapy of MHC-negative murine melanoma metastases.

23 August 2024

65

1 reference

Combination of intratumoral injections of vaccinia virus MVA expressing GM-CSF and immunization with DNA vaccine prolongs the survival of mice bearing HPV16 induced tumors with downregulated expression of MHC class I molecules.

23 August 2024

70

1 reference

Induction of protective CTL immunity against peptide transporter TAP-deficient tumors through dendritic cell vaccination

23 August 2024

82

1 reference

Immune escape phenotype of HPV16-associated tumours: MHC class I expression changes during progression and therapy.

23 August 2024

87

1 reference

TAP expression provides a general method for improving the recognition of malignant cells in vivo

23 August 2024

91

1 reference

Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival

23 August 2024

93

1 reference

Immunization with live HPV-16-transformed mouse cells expressing the herpes simplex thymidine kinase and either GM-CSF or IL-2.

23 August 2024

96

1 reference

23 August 2024

Identifiers

DOI

10.2217/FON.10.128

1 reference

23 August 2017

1 reference